Serbian President Aleksandar Vučić announced that substantial investments have been made in the country’s healthcare system, with a particular focus on the Clinical Center of Serbia. Over the past few years, 350 million euros have been allocated to this major healthcare facility. Vučić made these remarks during a visit to the site, where he inspected the final stages of the second phase of the center’s development.
The Clinical Center of Serbia, once fully operational, will boast 34 state-of-the-art operating rooms, including three hybrid rooms designed for advanced surgical procedures. This expansion is part of a broader effort to modernize Serbia’s healthcare infrastructure, which is supported by an annual healthcare budget of 5.2 billion euros.
During his visit, Vučić addressed the ongoing issue of costly treatments for rare diseases, particularly cystic fibrosis. He acknowledged public dissatisfaction regarding the allocation of these expensive therapies, which can cost between 200,000 and 500,000 euros per patient. Vučić noted that approximately 200 individuals require this treatment, resulting in a total financial requirement of 40 to 100 million euros. The president urged health officials to thoroughly assess the situation to determine feasible solutions.
This investment in the Clinical Center is part of a larger strategy to enhance healthcare services across Serbia. The first phase of the center’s development, which cost 132 million euros, has already been completed, while the ongoing second phase is divided into two parts, with the current phase costing 18 million euros and the subsequent phase estimated at 73 million euros. An additional 122 million euros have been allocated for equipping the facility.
Vučić’s visit to the Clinical Center was accompanied by Health Minister Zlatibor Lončar and the center’s director, Jelena Drulović. The president’s remarks highlighted the government’s commitment to improving healthcare services and addressing public concerns about the accessibility and affordability of treatments for rare diseases.
The Serbian government has been under pressure to address these issues, as citizens have expressed dissatisfaction with the current system, particularly regarding the prioritization of patients for expensive therapies. Vučić’s acknowledgment of these concerns and his directive to explore potential solutions indicate a willingness to engage with public feedback and improve healthcare outcomes.
This development is part of a broader context of healthcare improvements in Serbia, where investments in infrastructure and personnel have been ongoing. Previous phases of the Clinical Center’s development and other healthcare projects have laid the groundwork for these recent advancements. However, skepticism remains about the effective management and allocation of funds within the healthcare system.
As the government continues to invest in healthcare, the focus will likely remain on ensuring that these investments translate into tangible improvements in patient care and access to necessary treatments. The outcome of these efforts will be closely monitored by both the public and healthcare professionals, as the country seeks to enhance its healthcare services and address longstanding challenges in the sector.
